Pulmonary Disease Doctors in Ogden, UT Accepting Medicare

6 Pulmonary Disease doctors found. Showing 1 - 6

Gary K Goucher, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, #3815, Ogden, UT 84403 Phone: 801-387-2575    Fax: 801-387-2585

Daniel Kotok, Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4403 Harrison Blvd Ste 4410, Ogden, UT 84403 Phone: 801-387-6850    Fax: 801-387-6855

Alan R Abdulla, MD Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4403 Harrison Blvd, #3620, Ogden, UT 84404 Phone: 801-387-3525    Fax: 801-387-3530

Jeffrey A Abel, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Ste 3815, Ogden, UT 84403 Phone: 801-387-2575    Fax: 801-387-2585

Dr. William Joseph Walsh Iii, M.D. Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2740 Pennsylvania Ave, Ogden, UT 84401 Phone: 801-675-5624

Dr. Roger Paulman, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd, Ste 3815, Ogden, UT 84403 Phone: 801-387-2587    Fax: 801-387-2585

News Archive

Tourists to India need vaccination against Japanese encephalitis

Doctors in India are advising tourists to seek appropriate vaccination against Japanese encephalitis before visiting the country.

Breast imaging reports generated with automatic speech recognition more likely to contain errors

Breast imaging reports generated using an automatic speech recognition system are nearly six times more likely to contain major errors than those generated with conventional dictation transcription, a new study in Canada shows.

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

Cylene commences CX-4945 Phase I trial in multiple myeloma

Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.

Mass. high court upholds dismissal of lawsuits challenging Medicaid reimbursements

The Massachusetts' court has upheld the dismissal of lawsuits brought by some hospitals alleging the state's 2006 health law didn't reimburse them enough for caring for Medicaid patients.

Read more Medical News

› Verified 3 days ago